Overview

Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate risk of cancer incidence and mortality associated with the use of REGRANEX (becaplermin) in patients with diabetes who are members of a U.S. Veterans Health Administration.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborator:
Bedford Research Corporation, Inc.
Treatments:
Becaplermin
Platelet-derived growth factor BB
Criteria
Inclusion Criteria:

- Patients with diabetic foot ulcers who are members of the U.S Department of Veterans
Affairs Health Care System (VA)

Exclusion Criteria:

- History of cancer (including nonmelanoma skin cancer) prior to study entry